Small Molecules
29 November 2016
Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat for Treatment of Cystic Fibrosis28 November 2016
Foamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX10128 November 2016
Global Blood Therapeutics Announces Initiation of Phase 2a Trial of GBT440 in Idiopathic Pulmonary Fibrosis (IPF)28 November 2016
PharmaMar Begins a Phase I Study of PM1183 in Japan for the Treatment of Solid Tumors28 November 2016
Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing Phase 2 Clinical Trial in ER+/AR+ Breast Cancer28 November 2016
Santen Announces Phase III SAKURA Program Topline Results in Patients with Non-Infectious Uveitis of the Posterior Segment24 November 2016
NINLAROTM (ixazomib) Receives Conditional Approval from the European Commission to Treat Multiple Myeloma23 November 2016
Phase 3 study with filgotinib initiated in Crohn’s disease22 November 2016
Matinas BioPharma Initiates Enrollment and Commences Patient Dosing in Phase 2 Study of MAT2203 for the Treatment of Vulvovaginal Candidiasis21 November 2016
Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)21 November 2016
GSK Files Regulatory Submission in US for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD21 November 2016
Acorda to Discontinue Development of Dalfampridine for Treatment of Post-Stroke Walking Difficulties20 November 2016
Triphase Accelerator Corporation Announces Full Enrollment Results of Its Phase 1 Trial of Marizomib and Bevacizumab in Malignant Gliom20 November 2016
Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 201619 November 2016
Tenax Therapeutics Announces Completion of Enrollment for Phase 3 LEVO-CTS Trial in Cardiac Surgery17 November 2016
Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Atopic Dermatitis Study17 November 2016
Neos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, NT-0201, for the Treatment of ADHDNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports